Shares in gene therapy company MeiraGTx (Nasdaq: MGTX) shot up by around 20% in Thursday morning’s trading in New York.
The firm earlier announced an asset purchase agreement with the Johnson & Johnson (NYSE: JNJ) subsidiary Janssen, in which it exchanged future potential royalties for its Phase III candidate, botaretigene sparoparvovec, for a total of up to $415 million.
Under the terms of the deal, MeiraGTx is eligible to receive $130 million in upfront and near-term milestone payments, as well as an additional $285 million if the drug reaches commercialization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze